secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001193125-24-234391
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica out of Nasdaq compliance after director resignation; cure period granted
--------------------------------------------------------------------------------

- Craig Ballaron resigned from Board effective October 2, 2024.
- Board appointed Diem Nguyen to Audit Committee on October 7, 2024.
- Resignation caused loss of majority independent directors, violating Nasdaq Rule 5605(b)(1).
- Nasdaq provided cure period until next annual meeting or October 2, 2025.
- Company expects to regain compliance within the cure period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524234391/0001193125-24-234391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524234391/d796842d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-234391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer